Welcome to the BMS portal for health care professionals!
This portal is your one-stop-shop for all your needs and questions concerning BMS products in Switzerland! These are some examples of the things you can find:
- Rich media library with webinars, podcasts, HCP materials, patient brochures, and much more
- Detailed clinical data around our approved indications
- Information on ongoing clinical research in Switzerland
- Comprehensive calendar with BMS educational events and relevant national and international congresses
- The relevant BMS team members for your region and interest
News and recent approvals
Lisocabtagene maraleucel, CD-19 CAR T cell therapy
September 2023 – Swissmedic approved Lisocabtagene maraleucel (BREYANZI®) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL) or primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
BREYANZI®
▼ This drug is subject to additional monitoring. For further information, please refer to the product information on swissmedicinfo.ch.
More information
Thoracic cancer
July 2023 – Nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumor size ≥ 4cm or positive lymph node involvement) non-small cell lung cancer (NSCLC) with PD-L1 tumor expression ≥1% in adults
Melanoma
December 2022 – Nivolumab/Relatlimab for the first-line treatment of adults with unresectable or metastatic melanoma with PD-L1 expression < 1%.
Gastrointestinal cancer
July 2022 – Nivolumab in combination with Ipilimumab or with fluoropyrimidine- and cisplatinum-based chemotherapy for the first-line treatment of patients with advanced or metastatic oesophageal squamous cell carcinoma (PD-L1 ≥ 1%) not amenable to curative treatment
Genitourinary cancer
March 2022 – Nivolumab + ipilimumab for the first-line treatment of advanced or metastatic renal cell carcinoma
CAR T – Lisocabtagene maraleucel
March 2022 – Swissmedic approved Lisocabtagene maraleucel (liso-cel, BREYANZI®) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), or primary mediastinal large B-cell lymphoma (PMBCL) after two or more lines of systemic therapy.
BREYANZI®
▼ This drug is subject to additional monitoring. For further information, please refer to the product information on swissmedicinfo.ch.
More information
Ready to explore? Please use your existing DocCheck Login to access one of our therapeutic area portals, or access the comprehensive BMS medicines or news & events overview
10/2023 466-CH-2300011